Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 18, Issue 4, pp. 733-742
PubMed
Published By
Print ISSN
Online ISSN
History
- Received September 21, 2018
- Revision received December 9, 2018
- Accepted January 22, 2019
- Published first February 20, 2019.
Article Versions
- Previous version (February 20, 2019 - 10:38).
- You are viewing the most recent version of this article.
Copyright & Usage
©2019 American Association for Cancer Research.
Author Information
- Hiroki Irie1,*,
- Kimihiro Ito1,
- Yayoi Fujioka1,
- Kei Oguchi1,
- Akio Fujioka1,
- Akihiro Hashimoto1,
- Hirokazu Ohsawa1,
- Kenji Tanaka1,
- Kaoru Funabashi1,
- Hikari Araki1,
- Yuichi Kawai1,
- Tadashi Shimamura1,
- Renu Wadhwa2,
- Shuichi Ohkubo1, and
- Kenichi Matsuo1
- 1Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan.
- 2DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), DAICENTER, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki, Japan.
- ↵*Corresponding Author:
Hiroki Irie, Taiho Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba, Ibaraki 300-2611, Japan. Phone: 81-29-865-4527; Fax: 81-29-865-2170; E-mail: hiroki-irie{at}taiho.co.jp
April 2019
Volume 18, Issue 4
Volume 18, Issue 4
TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
Jump to section
Advertisement